Revenue
Margin
Demand
Guidance
Tone
Event Participants
Executives
3 Vijay Alilughatta, Pulkit Bhandari, Manish Tandon
Analysts
5 Shraddha Agarwal, Amit Chandra, Nitin Padmanabhan, Sukrit Patel, Sandeep Shah
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | $159.5 million | +1.1% QoQ CC; +0.7% QoQ reported; +8.9% YoY and +4% QoQ in INR terms, reflecting continued momentum despite mixed demand. |
| Order Book / TCV | $149.2 million | Multi-quarter low but with all-time high proportion of new business (existing + net new); Q1 is seasonally weak for renewals after prior quarter's ~$430 million bumper booking. |
| 10m+ Clients | +4 YoY | Increased count of $10 million+ clients, aiding reduction in client concentration risk. |
| Headcount | +5.2% QoQ; Gross additions 1,451 | Gross hires 50% higher QoQ; large deal was significant component but solid additions outside it as well. |
| Utilization | 85.1% | +80 bps QoQ, reflecting rigor in accelerated fulfillment and capability enrichment. |
| Voluntary Attrition | 9.6% | Industry-leading low; sixth successive quarter below 10%. |
| EBITDA Margin | Contracted 150 bps QoQ | Driven by ~2% pre-staffing/transition for large deal setup and ~1.5% higher other costs (travel/visa/training); offset by +0.8% forex and +1.3% bonus reversal. |
| PAT Margin | 12.2% | Contracted 220 bps QoQ. |
| Gross Margin | Contracted ~300 bps QoQ | Primarily due to mega deal ramp-up costs; expected to normalize post full ramp. |
| DSO | 75 days | Up from 71 days at FY26 end; management views 74-79 days as acceptable amid stretched payment terms. |
| Cash (incl. investments) | $317.5 million | Healthy balance sheet; OCF/EBITDA >70% this quarter with historically strong conversion above industry average. |
| ETR | 25.3% | For the quarter. |
| Diluted EPS | ₹8 per share | +0.9% YoY. |
| Service Line Revenue Share | 72.1% | +325 bps YoY; Data Engineering & Analytics +10.8% YoY reported, Cloud Infra & Security +5.6%, Products & Platforms +1.2%, Enterprise Apps -3.2%. |
Geographic & Segment Commentary
- BFSI: Delivered +8.3% QoQ CC growth as the strongest vertical driver, with contribution from the $210 million mega deal (execution started mid-February; mostly transition so far) plus underlying growth even ex-deal. Full revenue weight expected in Q3-Q4 with continued ramp in Q2.
- Healthcare & Life Sciences: Declined 3.8% QoQ; primarily portfolio and client-specific issues (consolidation out of 1-2 accounts) plus some biotech impact from FDA slowdowns/adverse decisions rather than broad macros. Management recovered ~75% of expected larger dip and sees growth resuming in subsequent quarters.
- Manufacturing & Consumer Services: Declined 2.3% QoQ; management less bullish on Europe and consumer services overall, with Africa performing well on a selective basis.
- Telecom, Media & Technology: Declined 9.1% QoQ; ex the largest client, performance is quite strong, and the headwind from that account is expected to mute going forward given limited further downside.
Company-Specific & Strategic Commentary
- AI-Native Transformation: Launched ZenSai Agent Mesh as a universal enterprise platform for discovering, building, deploying and governing autonomous AI agents at scale; actively rolling out AI-native offerings, expanding AI ecosystem partnerships and investing in AI-certified talent to help clients capture frontier/sovereign AI value with governance controls.
- AI Delivery Impact: Productionized agent-based SDLC/testing across global BFSI clients delivering 25%+ productivity uplift (44% code AI-generated) and 50-60% acceleration on large-scale migrations; re-platformed mainframe/COBOL estates with 40-60% effort savings via agentic workflows; scaled ZenCI family (QA agents, Azure AI for Agent Assurance, banking/risk agents, Guidewire suite, content factory for marketing campaigns) and won multiple AI-native SDLC projects using GitHub Copilot/Claude plus agentic methods.
- Talent & Culture: Ranked #6 in India's Best Companies to Work For 2026 (Great Place to Work) and #1 overall in IT Services category; supports industry-leading low attrition and ability to scale talent.
- Go-to-Market & Sales: Investing heavily in revamping/adding sales force (additions outpacing non-performer deletions) and SG&A to align with AI story and drive revenue growth; competitive intensity rising (including large peers entering SMB) but Zensar sees structural advantage in SMB agility vs. large players' bandwidth constraints.
- M&A: Actively evaluating scaled assets (north of $150-200 million revenue range; 2-3 under review) rather than tuck-ins, citing attractive pricing environment currently.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Margins (EBITDA/PAT) | Similar range to Q1 levels for Q2 and Q3; expansion thereafter | Priority on growth investments (SG&A, AI capabilities) and large-deal ramp over near-term margin expansion; margins to follow once ramp complete (from Q3 onward). |
| Book-to-Bill | Maintain 0.9x-1.1x of projected revenue | Can appear lower in coming quarters due to prior mega-deal ($~430 million) distortion; aspiration unchanged and focused on pipeline conversion. |
| Revenue Trajectory | Q2 better than Q1 | Qualitative; full mega-deal weight in Q3-Q4; HLS expected to grow subsequent quarters; overall demand mixed but volume growth broad-based. |
| Large Deal Pipeline | ~23% of total pipeline | Large deals defined as >$25 million TCV; composition historically stable in 20-30% range; no current mega deals in pipeline. |
Risks & Constraints
| Risk | Context |
|---|---|
| Macro & Demand Softness | Global macro remains uncertain with geopolitical volatility, trade shifts and policy changes weighing on investment decisions; IT resilient but clients shifting to AI-native models. Softness concentrated in HLS/MCS/TMT (ex-BFSI broad-based declines for second straight quarter); Europe and consumer less bullish. |
| Competitive Intensity | Rising across market (visible in peer results) including large peers carving out SMB units; management not overly concerned as large-firm structures lack SMB execution agility/bandwidth for smaller clients. |
| Deal Ramp & Margin Pressure | Pre-staffing/transition costs for $210 million mega deal (plus higher travel/visa/training) drove 150 bps EBITDA and ~300 bps gross margin contraction; full revenue weight only from Q3-Q4. |
| Client Concentration & Portfolio | Historical concentration risk mitigated by +4 $10m+ clients YoY; remaining softness mostly client-specific consolidations (esp. HLS) rather than structural portfolio issues. |
| Working Capital | Payment terms stretching industry-wide; DSO at 75 days (vs 71 at FY26-end) viewed as acceptable in 74-79 day range; cash conversion remains strong (>70% OCF/EBITDA). |
Q&A Highlights
BFSI Growth & Mega Deal Ramp
- Question: How much of the sharp 8% BFSI growth is from the $210 million deal ramp-up, and is it running ahead of plans that targeted material ramp in Q3? (Shraddha Agarwal)
- Answer: Contribution exists but not disclosed; BFSI grew even ex-deal. Deal started mid-February (half-quarter effect); mostly transition so far, not full revenues. Q2 continues ramp; full weight appears in Q3-Q4. (Manish Tandon)
Competitive Intensity in SMB
- Question: Commentary on competitive intensity from larger peers entering SMB via dedicated units? (Shraddha Agarwal)
- Answer: Intensity has increased with market conditions, but not worried—large firms' processes/structures lack SMB agility; limited bandwidth/talent focus when client is #350. (Manish Tandon)
Order Book & Pipeline
- Question: Is $149 million order intake a multi-quarter low, and what to expect for remaining TCV wins? Also, why aspirational book-to-bill only 0.9-1.1x given vertical leaks? (Shraddha Agarwal / Nitin Padmanabhan / Sandeep Shah)
- Answer: Seasonally weak Q1 (renewals in Q3/Q4); new-business mix at all-time high after bumper prior quarter (~$430 million). Maintain 0.9-1.1x aspiration; mega deal (1/3 of company revenue) distorts optics. Investing in sales force revamp (additions > deletions) and AI-aligned GTM. Large-deal pipeline ~23% (historically 20-30% range). (Manish Tandon)
Other Verticals Outlook
- Question: Will declines in MCS/HLS/TMT moderate or improve? How much of HLS drop is macro vs portfolio? (Nitin Padmanabhan / Amit Chandra)
- Answer: Less bullish on Europe/MCS; Africa selective strength; TMT solid ex-largest client (headwind muting). HLS mostly portfolio/client consolidations + some FDA/biotech impact (not macros); recovered ~75% of expected dip and expects subsequent growth. (Manish Tandon)
Margins Outlook
- Question: How to think about post-tax margins going forward, and is ~300 bps gross margin decline fully large-deal related? (Nitin Padmanabhan / Sandeep Shah)
- Answer: Similar to Q1 for next 1-2 quarters (Q2-Q3) as priorities are SG&A/AI capability investments + large-deal ramp; margins follow thereafter. Yes, primary gross margin pressure from mega deal; normalizes post-ramp. (Pulkit Bhandari / Manish Tandon)
Execution Priorities & Risks
- Question: Top 2-3 execution priorities next two quarters and biggest risks (demand shifts/competitive)? Also financial risks on margins/cash/balance sheet? (Sukrit Patel)
- Answer: (1-2) Make Zensar AI-native for self and clients; (3) smooth mega-deal ramp + SG&A investment for growth. Cash conversion strong (>70% OCF/EBITDA, historically above industry); DSO trajectory acceptable; no major receivable issues. (Manish Tandon / Pulkit Bhandari)
Headcount & Capital Allocation
- Question: How much headcount addition tied to large deal/rebadging? Plans for healthy cash (M&A/gaps)? (Amit Chandra)
- Answer: Large deal significant but good additions elsewhere too. Actively looking at scaled assets ($150-200m+ revenue range; 2-3 under review now)—right time given non-absurd pricing; no tuck-ins. (Vijay Alilughatta / Manish Tandon)
Key Takeaway
Zensar reported Q1 FY27 revenue of $159.5 million (+1.1% QoQ CC; +8.9% YoY INR) driven by BFSI strength (+8.3% QoQ CC, including early contribution from the $210 million mega deal) that offset declines in HLS (-3.8%), MCS (-2.3%) and TMT (-9.1%). Operational metrics improved with utilization at 85.1% (+80 bps), voluntary attrition at industry-low 9.6%, headcount +5.2% QoQ and +4 $10m+ clients YoY, while PAT margin contracted 220 bps to 12.2% and EBITDA 150 bps on large-deal pre-staffing (~2%) plus higher costs, partly offset by forex and bonus reversals. Strategically, the company launched ZenSai Agent Mesh and scaled ZenCI agentic platforms delivering 25%+ productivity and 40-60% effort savings, while investing in AI talent, sales force revamp and evaluating $150-200m+ M&A assets; cash stood at $317.5 million with strong conversion. Management expects Q2 sequential improvement, similar margins through Q3 amid ramp/investments (expansion thereafter), book-to-bill of 0.9-1.1x and HLS recovery, though macro uncertainty, vertical softness and competitive intensity remain watch points as AI-native execution and deal ramp progress.